Claritin
Mark-up of legislation that would enable Schering-Plough's allergy drug (loratadine) and six other "pipeline" drugs to receive a three-year patent extension is delayed until after the congressional recess. The patent for Claritin is set to expire in 2002; by extending its patent life, the "Drug Patent Term Restoration Review Procedures Act" (S 1172), introduced by Sen. Robert Torricelli (D-N.J.), likely would mean a delay in what promises to be a high-impact Rx-to-OTC switch product. From the competition's standpoint, such a delay would stave off a serious challenge for numerous existing OTC allergy products such as Warner-Lambert's Benadryl line, McNeil Consumer Healthcare's Tylenol Allergy items and certain products in Whitehall-Robins' Dimetapp line. Opponents of the bill say it would stifle generic competition, thus inflating consumer pricing
Learn what's happening at the US FDA. On the go.
More from Archive
- • By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
- • By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
